Acetylon begins study of drug candidate for multiple myeloma

09/22/2011 | Mass High Tech (Boston)

Acetylon Pharmaceuticals initiated a Phase I-IIa clinical study of ACY-1215, a drug candidate for relapsed and relapsed-refractory multiple myeloma. Phase I tests the class 2 histone deacetylase inhibitor as a treatment alone and in combination with standard therapies. In Phase IIa, researchers will evaluate the cancer's response to the drug.

View Full Article in:

Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC